Literature DB >> 22088667

[Morbi-mortality and use of recourses after acute coronary syndrome in a Spanish population].

A Sicras-Mainar1, J Fernández de Bobadilla, R Navarro-Artieda, I Martín, C Varela-Moreno.   

Abstract

OBJECTIVES: To describe the management of patients suffering acute coronary syndrome (ACS) and to determine its clinical and economic consequences in a Spanish population.
METHODS: A multicenter, retrospective claim database study including patient medical records from 6 primary care centers, two hospitals and two years of follow-up was carried out. Patients ≥30 years, suffering a first acute coronary syndrome (ACS), between 2003 and 2007, were included. Groups: acute coronary syndrome with and without ST segment elevation. VARIABLES: socio-demographic, co-morbidities, metabolic syndrome (MS), biochemical parameters, drugs, cumulative incidence (total mortality and cardiovascular events (CVE: including myocardial infarction, stroke and peripheral artery disease) and total costs. STATISTICAL ANALYSIS: logistic regression, Kaplan-Meier curves and ANCOVA; (P<.05).
RESULTS: A total of 1020 patients were included. Mean age: 69 years; males: 65%. Groups: ST segment elevation ACS (N=632; 62%). Co-morbidities: hypertension (56%), dyslipidemia (46%) and diabetes (38%). Prevalence of MS: 59% (CI 95%: 56-62%). All biochemical parameters had improved after two years of follow-up. The average total cost per patient was €14,069 (87% direct costs; 13% productivity loss costs). Direct costs: primary care (20%), specialty care (67%); hospitalization costs represented 63% of total costs. The average total cost for patients presenting more than one CVE was 22,750€ vs 12,380€ for those patients who suffered only one (P<.001). Cumulative incidence: total mortality 14%; CVE: 16%.
CONCLUSIONS: In the current clinical practice, and despite the clinical efforts carried out, patients with an ACS are still at a high risk of suffering further CVE, representing a high cost burden to the health care system.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22088667     DOI: 10.1016/j.rce.2011.07.007

Source DB:  PubMed          Journal:  Rev Clin Esp        ISSN: 0014-2565            Impact factor:   1.556


  2 in total

1.  Assessment of the length of sick leave in patients with ischemic heart disease.

Authors:  Nausica Català Tella; Catalina Serna Arnaiz; Jordi Real Gatius; Oriol Yuguero Torres; Leonardo Galván Santiago
Journal:  BMC Cardiovasc Disord       Date:  2017-01-18       Impact factor: 2.298

Review 2.  Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain.

Authors:  Alex de la Sierra; Xavier Pintó; Carlos Guijarro; José López Miranda; Daniel Callejo; Jesús Cuervo; Rudi Subirà; Marta Rubio
Journal:  Adv Ther       Date:  2015-10-26       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.